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Abstract
Introduction: Molecular characterization of the normal epithelial cell types that reside in the mammary gland is an 
important step toward understanding pathways that regulate self-renewal, lineage commitment, and differentiation 
along the hierarchy. Here we determined the gene expression signatures of four distinct subpopulations isolated from 
the mouse mammary gland. The epithelial cell signatures were used to interrogate mouse models of mammary 
tumorigenesis and to compare with their normal human counterpart subsets to identify conserved genes and 
networks.
Methods: RNA was prepared from freshly sorted mouse mammary cell subpopulations (mammary stem cell (MaSC)-
enriched, committed luminal progenitor, mature luminal and stromal cell) and used for gene expression profiling 
analysis on the Illumina platform. Gene signatures were derived and compared with those previously reported for the 
analogous normal human mammary cell subpopulations. The mouse and human epithelial subset signatures were 
then subjected to Ingenuity Pathway Analysis (IPA) to identify conserved pathways.
Results: The four mouse mammary cell subpopulations exhibited distinct gene signatures. Comparison of these 
signatures with the molecular profiles of different mouse models of mammary tumorigenesis revealed that tumors 
arising in MMTV-Wnt-1 and p53-/- mice were enriched for MaSC-subset genes, whereas the gene profiles of MMTV-Neu 
and MMTV-PyMT tumors were most concordant with the luminal progenitor cell signature. Comparison of the mouse 
mammary epithelial cell signatures with their human counterparts revealed substantial conservation of genes, 
whereas IPA highlighted a number of conserved pathways in the three epithelial subsets.
Conclusions: The conservation of genes and pathways across species further validates the use of the mouse as a 
model to study mammary gland development and highlights pathways that are likely to govern cell-fate decisions and 
differentiation. It is noteworthy that many of the conserved genes in the MaSC population have been considered as 
epithelial-mesenchymal transition (EMT) signature genes. Therefore, the expression of these genes in tumor cells may 
reflect basal epithelial cell characteristics and not necessarily cells that have undergone an EMT. Comparative analyses 
of normal mouse epithelial subsets with murine tumor models have implicated distinct cell types in contributing to 
tumorigenesis in the different models.
Introduction
The mammary gland comprises a ductal epithelial net-
work embedded in a stromal matrix. The ducts are com-
posed of an inner layer of luminal cells and an outer layer
of myoepithelial cells. Pregnancy is accompanied by the
expansion and differentiation of alveolar luminal cells,
resulting in secretory cells that produce and secrete milk.
Although the function of the mammary gland is pre-
served across species, marked anatomic differences exist
between human and mouse mammary tissue. The human
mammary gland is characterised by a branching network
of ducts that terminate in clusters of small ductules that
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constitute the terminal ductal lobular units (TDLUs). In
contrast, the mouse mammary epithelial tree does not
contain TDLUs, although small alveolar buds are formed
during each estrous cycle. Moreover, the human breast
parenchyma is significantly more fibrous than the mouse
stroma, which contains predominantly adipocytes.
Despite these architectural differences, accumulating evi-
dence suggests that remarkable parallels are found
between the hierarchy of epithelial cells that exist in the
mammary glands of humans and mice [1].
Distinct epithelial subtypes have been prospectively
isolated from both mouse [2-5] and human mammary
glands [6-10]. Functionally analogous subpopulations
have been identified: the MaSC-enriched/bipotent pro-
genitor, committed luminal progenitor and mature lumi-
nal cell subsets. In the mouse, MaSCs are found within
the basal CD49fhiCD29hiCD24+Sca1- subset (referred to
as MaSC-enriched), whereas committed luminal progeni-
tor cells exhibit a CD29loCD24+CD61+ (or Sca-1-CD24+)
phenotype, and mature luminal cells display a
CD29loCD24+CD61-phenotype [2,3]. In human mam-
mary tissue, the CD49fhiEpCAM-/lo  subpopulation has
been demonstrated to be enriched for MaSCs, based on
in vivo transplantation either into the mouse mammary
fat pad [7] or under the renal capsule [6]. Luminal pro-
genitor and differentiated cells prospectively isolated
from human breast tissue are characterized by
CD49fhiEpCAM+  and CD49f-EpCAM+  phenotypes,
respectively.
There are similarities as well as species-specific differ-
ences in the expression of cell-surface markers on the epi-
thelial subsets. Both the mouse and human MaSC-
enriched populations express high levels of CD49f. How-
ever, CD24 is a marker of epithelial cells in the mouse
mammary gland, but not in human breast tissue, where it
specifically marks luminal cells [3-5,7,11]. Significantly,
both the human and mammary MaSC-enriched popula-
tions lack expression of the steroid hormone receptors
ERα and PR [7,12]. Moreover, these MaSCs do not
express detectable levels of ERBB2/HER2, reminiscent of
the triple-negative receptor phenotype that characterizes
many basal cancers [13].
Understanding the relation between normal epithelial
cell types and the different molecular subtypes of breast
cancer is fundamental to gaining insight into cell types
predisposed to carcinogenesis. At least six distinct sub-
types of breast tumors have been defined on the basis of
gene expression profiling. These include the luminal A
and B, basal-like, claudin-low, HER2/ERBB2-overex-
pressing, and normal breast-like subtypes [14]. We
recently used the emerging human mammary hierarchy
as a framework for understanding aberrant cell subsets
that may arise during breast oncogenesis [7]. The clau-
din-low subtype was found to be most closely associated
with the gene signature of the MaSC-enriched popula-
tion, whereas the molecular profiles of the basal-like sub-
type of breast cancer showed remarkable concordance
with the luminal progenitor gene signature. Not surpris-
ingly, the expression profiles of the luminal A and B sub-
types were closest to that of mature luminal epithelial
cells. Interestingly, the molecular portrait of premalig-
nant tissue from BRCA1 mutation carriers, who usually
develop basal-like breast cancers, showed striking simi-
larity to the luminal progenitor signature [7].
In the context of the mouse mammary gland, transcrip-
tome analyses of epithelial cells have highlighted the dif-
ferences between basal and luminal cells and revealed a
number of potential regulators [5,15]. Here we performed
genome-wide transcriptome analyses of three different
mouse epithelial subpopulations and established path-
ways that are conserved in functionally equivalent sub-
sets in humans by using specific gene signatures. We
further used these signatures to interrogate mouse mod-
els of mammary tumors, providing insight into cell types
that contribute to breast oncogenesis.
Materials and methods
Mice and mammary cell preparations
A single cell suspension of mammary cells was prepared
from freshly harvested mammary glands and sorted by
flow cytometry, as previously described [3]. Mice were on
a pure FVB/N background. All experiments were
approved by the WEHI Animal Ethics Committee, and
the care of animals was in accordance with institutional
guidelines. Experiments using human tissue obtained
from the Royal Melbourne Hospital Tissue Bank were
approved by the Human Research Ethics Committees of
The Walter and Eliza Hall Institute of Medical Research
and Melbourne Health.
Antibodies, staining and cell sorting
Unless otherwise specified, antibodies for flow cytometry
were obtained from BD Pharmingen. Antibodies against
mouse antigens were PE-conjugated antibody to CD24,
FITC-conjugated antibody to CD29 (clone HMbeta1-1
from H. Yagita) [16], biotin-conjugated antibodies to
CD31, CD45, and TER119, and APC-conjugated anti-
body to CD61 (Caltag). Antibodies used for human anti-
gens have previously been described [7]. The Alexa Fluor
647 anti-human CD24 antibody (Biolegend) was used for
a n a l y s i s  o f  h u m a n  b r e a s t  e p i t h e l i a l  s u b s e t s .  A n t i b o d y
staining and cell sorting was as previously described [3].
Data were analyzed by using WEASEL software [17].
RNA preparation and quantitative RT-PCR analysis
Total RNA was isolated from primary mammary cell sub-
populations with the RNeasy Micro kit (Qiagen). Reverse
transcription by using oligo(dT) primer and MoloneyLim et al. Breast Cancer Research 2010, 12:R21
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murine leukemia virus reverse transcriptase (Invitrogen)
was according to the manufacturer's protocol. Quantita-
tive RT-PCR was carried out by using a Rotorgene RG-
6000 (Corbett Research) and SensiMix (dT) DNA kit
(Quantace) under the following conditions: 10 min at
95°C followed by 35 cycles consisting of 15 seconds at
95°C, 20 seconds at 62°C, and 20 seconds at 72°C. Gene
expression was determined with the Rotor-Gene software
(version 1.7). The primer sequences used are listed in
Supplementary Methods in Additional file 1.
Microarray hybridizations
Total RNA was purified from sorted cell populations by
using the RNeasy Micro kit (Qiagen). RNA quality was
assessed with the Agilent Bioanalyzer 2100 (Agilent
Technologies) by using the Agilent RNA 6000 Nanokit
(Agilent Technologies) according to the manufacturer's
protocol. Up to 500 ng of RNA was labeled with the stan-
dard Total Prep RNA amplification kit (Ambion), and
complementary RNA (1.5 μg) was hybridized to Illumina
MouseWG-6 v2.0 BeadChips. After washing, the chips
were coupled with Cy3 and scanned by using an Illumina
BeadArray Reader. Unnormalized summary probe pro-
files, with associated probe annotation, were output from
BeadStudio.
Statistical analyses
Microarray data were analyzed by using the limma pack-
age of the Bioconductor open-source software project
[18,19], as described in more detail later.
Microarray data analysis: normal cell subpopulations
Raw intensities were normalized by using the neqc func-
tion, which performs normexp background correction
and quantile normalization by using control probes [20].
Probes were filtered if not detected in any sample (detec-
tion p value, 0.01). The mouse data are deposited as GEO
series GSE19446, and the human, as GSE16997.
Microarray data analysis: mouse model tumors
Expression profiles of mouse tumors were downloaded
from GEO series GSE3165 [21]. Fifty-six Agilent arrays
(Agilent-011978 Mouse Microarray G4121A) profiling
mouse tumor models of interest were included in the
analysis. The samples and arrays are described by Her-
schkowitz et al. [14]. Data analysis used the raw Agilent
Feature Extraction data files and probe annotation from
GEO. Control probes were filtered, and then expression
values were normexp background corrected with offset
16 [20], and then log-ratios were global loess normalized
[22]. Two MMTV-Wnt-1 samples and one MMTV-Neu
sample were removed as outliers on the basis of unsuper-
vised clustering.
Subpopulation expression signatures
Pairwise comparisons were made between the three epi-
thelial cell populations by using empiric Bayes-moder-
ated  t  statistics [19] and array quality weights [23].
Allowance was made for possible correlations between
RNA samples drawn from the same pool of mice [24].
The false discovery rate (FDR) was controlled by using
the Benjamini and Hochberg algorithm. Probes with FDR
< 0.05 and fold-change > 1.5 were judged to be differen-
tially expressed. For each subpopulation (MaSC-
enriched, luminal progenitor, and mature luminal), signa-
ture probes were defined as those that were significantly
differentially expressed in the same direction versus both
of the other two cell subpopulations. For stromal cells,
the signature probes were defined relative to the three
epithelial cell populations.
For each target sample (mouse tumor or normal mouse
mammary cell subpopulation), a set of signature scores
was computed to measure the transcriptional activity of
each mouse cell subpopulation in that sample, by using a
method previously described [7]. The signature score is
essentially the average log-expression of the signature
genes in the target sample, weighted by the direction and
magnitude of change of those genes in the mouse sub-
population used to define the signature. Higher scores
indicate that the transcriptional signature of the mouse
cell subpopulation is found in the target sample.
Conserved signature genes
A larger set of mouse signature genes were defined by
using the "nestedF" multiple-testing option of limma with
FDR < 0.1. The 1.5 fold-change threshold was main-
tained. Mouse and human probes were matched by gene
symbol by using the Jackson Laboratory orthology report
of 13 November 2009 [25]. If multiple probes mapped to
the same symbol, the probe with the highest average log-
expression was used. Human signature genes were
defined as for mouse, with the multiple testing step
repeated only for those human genes with orthologues
among the mouse signature genes.
Ingenuity pathway analysis
Ingenuity Pathway Analysis (IPA) [26] was conducted on
conserved signature genes. For the MaSC-enriched sub-
population, only the top 300 signature genes were used,
to make the numbers comparable for the different sub-
populations. The signature sets were overlaid with
canonic pathways. Canonic pathways were selected based
on known biologic significance of the most highly over-
lapping pathways, and were displayed by using "subcellu-
lar layout". Direct associations between signature genes
were drawn by using the "connect" option. The luminal
progenitor signature set was too small to generate con-
nections, so direct associations were drawn from the KIT
and CYP24A1 genes by using the "grow" option. Genes
without connections to other signature genes were
removed from the final figures.Lim et al. Breast Cancer Research 2010, 12:R21
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Results
Derivation of distinct gene signatures for mouse mammary 
cell subpopulations
Freshly sorted cell subpopulations (> 90% purity) were
prepared from mouse mammary glands for gene profiling
analysis. These subpopulations corresponded to the
MaSC-enriched (CD29hiCD24loCD61+), luminal progeni-
tor (CD29loCD24+CD61+), mature luminal
(CD29loCD24+CD61-), and stromal cell (CD29loCD24-)
fractions. Representative FACS dot plots depicting the
four mouse cellular subsets and comparison with the
analogous subpopulations found in human breast tissue
[7] are shown in Figure 1. For human mammary cells, the
subpopulations include the MaSC-enriched
(CD49fhiEpCAM-), luminal progenitor
(CD49f+EpCAM+), mature luminal (CD49f-EpCAM+),
and stromal cell (CD49f-EpCAM-) fractions. Although
CD24 is expressed in all epithelial subsets in mouse
mammary epithelium [3-5], within human breast tissue,
it marks luminal progenitor and mature luminal cells
(Figure S1 in Additional file 2).
The Illumina mouse WG-6 v2.0 platform was used for
arraying the four murine cell subpopulations, incorporat-
ing five biologic replicates for the three epithelial popula-
tions and three replicates for the stromal subset.
Importantly, the RNA was not subjected to an amplifica-
tion step before preparation of labeled cRNA, to avoid
potential skewing of expression data. Unsupervised clus-
tering revealed that the four subpopulations had distinct
gene expression profiles (Figure S2 in Additional file 3).
Gene expression signatures were derived for the four
murine cell subpopulations, by using a method we
applied previously to the analogous human subpopula-
tions [7]. In brief, signature genes were chosen that were
consistently up- or downregulated in that subpopulation
(with fold-change at least 1.5 and FDR < 0.05) versus each
of the other populations (Table 1). This selects a set of
signature genes that strongly characterize each subpopu-
lation by their unusually high or low transcriptional activ-
ity.
Mouse gene signatures correlate with specific mouse 
models of breast cancer
First, we used the signature genes to identify relations
between tumor cells and normal epithelial cell types.
Genetically engineered mouse models of mammary tum-
origenesis have been previously described and include
the mouse mammary tumor virus (MMTV)-Wnt-1,
MMTV-Neu,  MMTV-PyMT,  WAP-Myc,  WAP-Int3
(Notch-1) transgenic, and p53-null mouse models [27].
We interrogated the expression profiles of whole mam-
mary tumors isolated from these mouse models [14] for
the expression signatures characteristic of our mouse
MaSC-enriched, luminal progenitor, mature luminal, and
stromal subpopulations. These analyses were carried in
an analogous manner to that described for comparison of
human mammary cells with the different breast cancer
subtypes [7]. In brief, the signature genes for each sub-
population were used to construct an index of transcrip-
tional activity characteristic of that subpopulation. These
indices, or expression signatures, were then computed for
each tumor sample. The MaSC transcriptional signature
was found to be highest in MMTV-Wnt-1  and  p53-/-
tumors (Figure 2a). Robust results were obtained even
Figure 1 Comparison of analogous human and mouse mammary cell subsets. Representative FACS dotplots of (a) Lin- human mammary cells 
isolated from the reduction mastectomy specimen of a 27-year-old woman labeled with CD49f and EpCAM antibodies and (b) Lin- mouse mammary 
cells isolated from 8-week-old virgin FVB/N mice labeled with CD24, CD29, and CD61 antibodies. The four analogous mammary subsets correspond 
to the MaSC-enriched (human CD49fhiEpCAM-; mouse CD29hiCD24+CD61+), luminal progenitor (human CD49f+EpCAM+; mouse CD29loCD24+CD61+), 
mature luminal (human CD49f-EpCAM+; mouse CD29loCD24+CD61-), and stromal (human CD49f-EpCAM-; mouse CD29loCD24-) mammary cell sub-
populations. LP: luminal progenitor; Lum: luminal; ML: mature luminal; MS: MaSC-enriched;   Str: stromal.
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though the p53-/- tumors are on a different background
compared with the other tumor types (BALB/c versus
FVB/N). In contrast, the luminal progenitor signature
was highest in MMTV-Neu and MMTV-PyMT tumors.
The mature luminal signature was highest in MMTV-Myc
tumors. The tumors arising in MMTV-Int3 mice did not
correspond to a specific subset within the mammary epi-
thelial hierarchy. As anticipated, the mouse stromal sig-
nature was not apparent in any of the mammary tumor
profiles, thus reflecting the epithelial content of the
tumors. Figure 2b summarizes potential relations
between normal epithelial cell types and commonly used
models of mammary tumorigenesis.
Comparison of the expression profiles of human and 
mouse subpopulations
We previously reported the expression profiling of
human mammary epithelial cell subpopulations, by using
freshly sorted cells, unamplified material, and the Illu-
mina platform [7]. The human and mouse gene expres-
sion profiles were first compared in a multidimension
scaling (MDS) plot analysis, an unsupervised two-dimen-
sional display of differences between profiles. As
expected, samples separated clearly by species (Figure
3a). After normalizing for species differences, however,
the samples clustered clearly by cell subtype (Figure 3b),
showing that relative expression patterns across the cell
subtypes are largely conserved between the two species.
Dimension 1 distinguishes stromal cells from luminal
cells, whereas dimension 2 distinguishes stem cells from
others. The luminal progenitor and mature luminal sub-
populations shared the greatest similarity, especially in
the case of mouse.
To relate the two species more closely, we examined the
transcriptional activity scores of the mouse subtype-spe-
cific signature genes in each of the human RNA samples.
This demonstrated a conserved expression profile for
each epithelial cell subtype across the two species. For
each subpopulation, the mouse transcriptional signature
was consistently highest in the corresponding human
subtype for every biologic replicate (Figure 3c). The two
luminal subtypes showed intermediate cross-over tran-
scriptional activity with each other, whereas the tran-
scriptional activity of the MaSC-enriched subset was
relatively specific (Figure 3c).
Conservation of signature genes between mouse and 
human mammary subpopulations
Next we looked for genes in common between the mouse
and human signatures for each epithelial subpopulation.
For this analysis, we used a more comprehensive set of
signature genes, by loosening slightly the FDR criteria, as
described in Methods (Tables S1-S3 in Additional files 4,
5, and 6). Of a total of 8,451 mouse probes that were sig-
nature probes for the three epithelial subpopulations,
4,758 unique mouse genes with human orthologues were
found, of which 1,204 (25%) were found to be signature
genes for the corresponding human subpopulation (Table
2). As expected, the MaSC-enriched subpopulation had
the largest number of signature genes and the highest
conservation rate between species, with 489 shared
upregulated and 428 shared downregulated genes (Table
2), indicating strong conservation in basal lineage genes.
The lower degree of conservation evident in the luminal
progenitor and mature luminal cell signatures in part
reflects the closer relation between these two subpopula-
Table 1: Number of signature probes and genes for each mouse cell subpopulation (stringent criteria)
Mammary epithelial cell 
subsets
Mouse
probes
Unique
mouse genes
Mouse genes with human 
orthologues
MaSC-enriched
Upregulated 2,616 1,790 1,438
Downregulated 2,305 1,620 1,316
Luminal progenitor
Upregulated 521 373 286
Downregulated 170 132 111
Mature luminal
Upregulated 1,026 733 569
Downregulated 1,034 740 624
Stroma
Upregulated 1,933 1,273 998
Downregulated 1,264 911 773
Stringent signature probes were chosen by using fold-change > 1.5 and global FDR < 0.05.Lim et al. Breast Cancer Research 2010, 12:R21
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tions but also suggests that they may be more heteroge-
neous than previously anticipated.
The conserved upregulated genes in the MaSC-
enriched population spanned diverse gene ontology
groups, including transcription factors (for example, Irx4,
Mef2c, Slug, Egr2, Twist2, Tbx2, Id4, p63, and Sox11),
cytokeratins (Krt5, 14, 16), and plasma membrane pro-
teins (for example, Lgr6 and the receptors for Oxytocin,
Oncostatin M, and Lif). The Notch ligand Jag2 was highly
expressed in this subpopulation, and its product may
directly signal through Notch receptors expressed on
adjacent luminal cells [28]. The Wnt/β-catenin pathway is
anticipated to be active in self-renewing MaSCs, compat-
ible with the observation that Fzd8 and Tcf4 are compo-
nents of the conserved upregulated gene signature in the
MaSC-enriched population. The Wnt-pathway inhibitors
Wif1  and Dkk3, however, were also found to be abun-
dantly expressed. These antagonists may be expressed
and secreted by mature myoepithelial cells present within
this population to attenuate Wnt signal transduction in
the basally located MaSCs.
For the luminal progenitor signature, Kit  (receptor
tyrosine kinase), Elf5 (Ets transcription factor), Cyp24A1
(vitamin D metabolizing enzyme), Lbp, and Cxcr4 were
highly expressed in both species. Aldh1a3  was also
upregulated in luminal progenitor cells versus other cell
types, although another isoform Aldh5a1 was identified
in the luminal-restricted population isolated by Raouf et
al. [11]. Interestingly, virtually all the ALDH activity in
human breast epithelium resides within the luminal pro-
genitor population (unpublished data) rather than the
more primitive mammary stem cell subset [29]. In mature
luminal cells, highly expressed genes included the tran-
scription factors Foxa1, Myb, estrogen receptor (ER), pro-
gesterone receptor (PgR), and Tbx3, as well as the
prolactin receptor (Prlr) and Rank ligand (Tnfsf11).
Quantitative RT-PCR analysis was used to validate a
number of genes in the conserved signatures, examples of
which are shown in Figure 4. In the MaSC-enriched pop-
ulation, the Wnt inhibitory factor Wif1 and transcription
factors Δ Np63, Tbx2, and slug (snail2), were preferen-
tially expressed, thus validating the Illumina microarray
data. Human NOTCH-4 was most highly expressed in the
basal population, compatible with the findings of Raouf et
al. [11] but differing from the mouse Notch-4 gene, which
was expressed in all epithelial subsets at low levels [28].
Figure 2 Comparison of gene expression profiles of normal mouse mammary cell subsets with mammary tumor models. (a) Box plots of sig-
nature expression scores by the mouse mammary tumor model for each subset. The MaSC-enriched signature scores are highest in the MMTV-Wnt-
1 and p53-/- tumors, whereas the luminal progenitor signature scores are highest in the MMTV-Neu and MMTV-PyMT models. *P < 0.05, **P < 0.01, ***P 
< 0.001. Mammary tumor datasets are from Herschkowitz et al. [14]. (b) Schematic model of the mouse mammary epithelial hierarchy and possible 
relations with mouse mammary tumor models. Subpopulations containing MaSCs, luminal progenitor, and mature luminal cells are defined by differ-
ential expression of CD24, CD29, and CD61. Gene expression profiling of these subpopulations revealed similarities to specific mouse mammary tumor 
models, depicted on the right side.
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C-Kit, Cyp24A1, and Elf5 were predominantly expressed
in the luminal progenitor population in both species.
Although low levels of KIT mRNA were evident in the
human MaSC-enriched population, FACS analysis has
shown that KIT protein is selectively expressed by human
luminal progenitor cells (data not shown). As expected,
Krt18,  ERα, and PgR  were preferentially expressed in
mature luminal cells in both mouse and human, consis-
tent with immunostaining of freshly sorted cells [7,12].
The differential expression of other genes, including
RankL,  amphiregulin,  Wnt4, and ErbB2  was also con-
firmed in the mouse and human subsets (data not
shown).
Conservation of canonic pathways between mouse and 
human subpopulations
To identify pathways and gene networks active in both
human and mouse, the conserved signature genes for
each epithelial subpopulation were analyzed by using the
Ingenuity Pathway Analysis (IPA) software [26]. For each
subpopulation, canonic molecular pathways that had
greatest overlap with the conserved signature genes were
selected. The resulting pathways therefore center on con-
served genes characteristic of the various epithelial popu-
lations. In the MaSC-enriched subset, several pathways
w e r e  f o u n d  t o  b e  c o n s e rv e d  a c r o s s  s p e c i e s,  f o r m i n g  a
number of specific nodes that include the ephrin recep-
tor, integrin, interleukin-8, p53, and Wnt/β-catenin sig-
naling pathways (Figure 5). Interestingly, IL-8 has
recently been implicated in the cancer stem cell signature
of the ALDH+ population in several breast cancer cell
lines. IL-8 was also shown to enhance mammosphere for-
mation and ALDH activity in these cell lines [30].
For the luminal progenitor cell population, the network
was expanded through the addition of neighboring genes
(depicted in white, Figure 6), as few connections were evi-
Figure 3 Colocalization of gene signatures of corresponding human and mouse mammary cell subsets. (a) Multidimension scaling (MDS) plot 
showing clear separation of the MaSC-enriched (MS), the two luminal (luminal progenitor, LP; and mature luminal, ML), and stromal (str) cell subpop-
ulations in both human (h) and mouse (m) mammary glands. (b) MDS plot after normalization for dimension 1 in (a), representing the differences 
across species. This demonstrates colocalization of analogous human and mouse mammary cell subsets. (c) Dot plots demonstrating the highest co-
localization of gene signatures between corresponding subsets compared with other subsets.
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dent. Conserved pathways include the Toll-like receptor,
vitamin D receptor, and Erk/Mapk signaling pathways.
Kit, Elf5, and Cyp24A1 represent highly differentially
expressed genes that form key components of the luminal
progenitor cell signature. In the mature luminal progeni-
tor subset, the steroid hormone receptor, HER2/erbB2,
and Notch signaling networks emerged as conserved
pathways across species (Figure 7).
Discussion
In this study, we describe a comparative transcriptome
analysis of functionally analogous human and mouse
mammary cell populations using an Illumina platform.
Four prospectively isolated populations were evaluated,
corresponding to those enriched for basal/mammary
stem cells, committed luminal progenitor, mature luminal
epithelial, and stromal cells. Distinct gene signatures were
apparent for the mouse subpopulations, reminiscent of
that found for human mammary cell subsets [7]. Com-
parison of the mammary epithelial signatures across
human and mouse, combined with Ingenuity pathway
analysis, revealed a number of conserved genes and path-
ways that are likely to regulate key processes during
mammary ontogeny.
The MaSC-enriched subset exhibited the largest num-
ber of genes conserved across species. This subset com-
prises stem cells, likely basal progenitor cells, as well as
mature myoepithelial cells. These cells share many com-
mon cell-surface markers that have impeded efforts to
fractionate this population. Multiple transcriptional reg-
ulators (Irx4, Mef2C, Slug, Egr2, Twist2, Tbx2) were found
to be highly expressed in this basal subset. Interestingly,
the leucine-rich repeat-containing G protein-coupled
receptor Lgr6 [31], which belongs to the same subgroup
as Lgr5, a stem cell marker of small intestine, colon, and
hair follicles [32], was identified as a component of the
MaSC-gene signature. A prominent integrin network also
emerged; these proteins play an important role in mediat-
ing interactions between basal cells (including MaSCs)
and the underlying extracellular matrix. Of relevance,
several genes attributed to cells that have undergone an
EMT [33], such as slug, vimentin, and absence of E-cad-
herin expression, also characterize basal cells in the
mammary gland. Therefore, the expression of these genes
in breast tumor cells may indicate the acquisition of basal
cell characteristics rather than an EMT. The recently
described link between Wnt signaling and the EMT [34]
may also reflect an active Wnt pathway in MaSCs or
other cells in this basal population.
Kit, Cyp24A1, and Elf5 appear to be defining markers
of committed luminal progenitor cells in both species.
Interestingly, the tyrosine kinase KIT was reported to be
overexpressed in basal breast cancers [35] and BRCA1-
associated basal cancers [7], suggesting that it may serve
as a useful prognostic marker or therapeutic target. Elf5
has been demonstrated to be important for driving alveo-
lar cell differentiation during pregnancy [36] but may play
an earlier role in regulating luminal cell-fate decisions.
Interestingly, triple-negative breast cancer patients have
been shown to have lower serum vitamin D levels, and
Cyp24A1 is known to catabolize both 25-hydroxyvitamin
D and 1,25-dihydroxyvitamin D. It is therefore tempting
to speculate that higher levels of CYP24A1 might be
linked to increased breast cancer risk [37]. Other inter-
esting candidates include CXCR4, a receptor implicated
in mediating metastasis of breast cancer cells through its
ligand SDF-1 [38], and CD14 and lipopolysaccharide-
binding protein (LBP), which are implicated in Toll-like
Table 2: Number of mouse signature probes and genes conserved in human mammary epithelial cell subpopulations
Mammary epithelial 
cell subsets
Mouse
probes
Unique
mouse genes
Mouse genes with 
human orthologues
Mouse genes 
conserved in humans
MaSC-enriched
Upregulated 2,811 1,928 1,551 489
Downregulated 2,474 1,729 1,395 428
Luminal progenitor
Upregulated 604 435 333 58
Downregulated 203 152 128 14
Mature luminal
Upregulated 1,112 784 606 116
Downregulated 1,247 889 745 99
Inclusive sets of signature probes were chosen by using "nestedF" with fold-change > 1.5 and FDR < 0.1.Lim et al. Breast Cancer Research 2010, 12:R21
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receptor signaling and LPS-mediated inhibition. In the
mature luminal population, active pathways identified by
IPA include the Wnt ligands (Wnt4, 5A, 7B), which may
act on MaSCs to enhance their self-renewal or prolifera-
tion. Expression of the transcriptional regulator Lmo4
was downregulated in the mature luminal subset, consis-
tent with findings that this oncoprotein is important for
promoting mammary epithelial cell proliferation and
inhibiting differentiation [39,40]. Conversely, the expres-
sion of other transcriptional regulators (ERα, Myb, PR,
and Cited1) was significantly upregulated in mature lumi-
nal cells.
A high degree of concordance was found between the
expression profiles of the basal and mature luminal cell
subsets in the mouse mammary gland described here and
those previously reported [5,15], although the luminal
Figure 4 Quantitative RT-PCR analysis of specific genes that define human and mouse mammary epithelial subsets. Histograms depicting 
the relative fold difference in RNA expression between specific mammary epithelial cell subsets relative to other subsets in mouse and human mam-
mary tissue. Expression analysis was relative to 18S rRNA. Examples of genes primarily expressed in the (a) MaSC-enriched subset, (b) luminal progen-
itor subset, and (c) mature luminal subset. At least three independent samples from either mouse or human mammary cell populations were 
evaluated for each gene. Data represent mean ± SEM. Statistically significant differences of P < 0.05 (t test) were observed between expression in the 
basal (MS) versus the two luminal subpopulations (ML and PL) for all genes except mouse Notch4.
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progenitor expression profiles proved to be more diver-
gent. For the basal/MaSC-enriched population, con-
served pathways such as the Ephrin, Wnt, and
extracellular matrix networks were also identified as
nodes in interaction mapping of the basal subset by Ken-
drick et al. [15]. Similarly, the gene expression profiles of
the mature luminal subset (reported here) shared sub-
stantial overlap with that of the ER+ population described
by Kendrick et al. [15], with the ER/glucocorticoid recep-
tor signalling network emerging as one of the predomi-
nant nodes. The expression profile of the luminal
progenitor subpopulation, however, exhibited substantial
differences from that of the ER- [15] and Ma-CFC subsets
[5], indicating that they may represent distinct or hetero-
geneous cell populations. Nevertheless, the Kit and TLR
signaling pathways identified here using Ingenuity Path-
way analysis were also revealed as distinct modules in the
ER- network by ROCK analysis [15]. The gene profiles
determined for the same three epithelial subsets isolated
from human mammary tissue by Raouf et al. [11] show
similarities but also differences that likely reflect short-
term culture of their cells before gene expression studies
[11].
Interrogation of breast cancer subtypes with the gene
signatures of normal human epithelial cell subsets has
revealed striking relations. Intriguingly, the luminal pro-
genitor gene signature shared marked similarity with the
basal subtype of breast cancer and preneoplastic breast
tissue from BRCA1  mutation carriers [7]. Moreover,
aberrant luminal progenitor cells were detected in
BRCA1 mutation carriers, suggesting that they serve as a
target population for further oncogenic events [7]. To
extend these studies and identify candidate cell types that
might contribute to oncogenesis in mouse models, we
explored the link between the mouse mammary epithelial
hierarchy and models of mammary tumorigenesis. The
MaSC-enriched transcriptional signature was highest in
MMTV-Wnt-1  and  p53-/- tumors, indicating that cells
within these tumors exhibit similarities with MaSCs or
basal progenitors. Although cancer stem cell populations
have been identified in these tumors [41-43], one cannot
conclude that these bear resemblance to MaSCs based on
Figure 5 Conserved genes and pathways across the human and mouse mammary stem cell-enriched subsets. Ingenuity pathway analysis of 
conserved genes between mouse and human, and mouse genes with human orthologues, in the MaSC-enriched subset. The genes are divided ac-
cording to the cellular distribution of the proteins for which they encode. The active pathways in each subset are represented on the right. Red rep-
resents upregulated genes, whereas green depicts downregulated genes. White symbols depict neighboring genes. The intensity of color represents 
the average log fold-change in a given population relative to the other epithelial subsets.Lim et al. Breast Cancer Research 2010, 12:R21
http://breast-cancer-research.com/content/12/2/R21
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expression profiling studies. Rather, the molecular pro-
files may indicate a cell type that has been expanded dur-
ing tumor progression. It is notable that preneoplastic
tissue from MMTV-Wnt-1  transgenic mice has been
shown to harbor an expanded mammary stem cell pool as
well as aberrant bipotent progenitor cells, indicating that
more than one cell of origin may exist in the Wnt-1 model
[42].
The luminal progenitor signature was highest in
MMTV-Neu  and  MMTV-PyMT  tumors. Compatible
with this observation for the MMTV-Neu model, FACS
analyses of these tumors has indicated a homogeneous
population of cells expressing high levels of the luminal
progenitor marker CD61+ [42]. Thus, luminal progenitor
cells may have undergone expansion in these tumors. The
MMTV-Neu strain, however, does not accurately recapit-
ulate HER2-overexpressing cancers arising in women,
because  MMTV-Neu  t u m o r s  d o  n o t  s h o w  s i g n i f i c a n t
gene overlap with the HER2-positive subtype but are
more similar to human "luminal" tumors [14]. Interest-
ingly, the mature luminal signature was highest in
MMTV-Myc tumors. The small progenitor subset in the
'mature' population [2,28], rather than the differentiated
luminal cells, is likely to contribute to tumorigenesis in
this model.
Conclusions
The high degree of conservation between analogous epi-
thelial subtypes across species supports the use of mice as
a model system to study normal mammary gland devel-
opment and oncogenesis. The conserved pathways pin-
point those that are likely to be involved in cell-fate
decisions and lineage differentiation in the basal or lumi-
nal epithelial cell lineages. In the context of breast cancer,
genes within the conserved signatures, such as those that
characterize the more purified luminal progenitor subset
Figure 6 Conserved genes and pathways across the human and mouse luminal progenitor cell subsets. Ingenuity pathway analysis of con-
served genes between mouse and human, and mouse genes with human orthologues, in the luminal progenitor subset. The genes are divided ac-
cording to the cellular distribution of the proteins for which they encode. The active pathways in each subset are represented on the right. Red 
represents upregulated genes, whereas green depicts downregulated genes. White symbols depict neighboring genes. The intensity of color repre-
sents the average log fold-change in a given population relative to the other epithelial subsets.Lim et al. Breast Cancer Research 2010, 12:R21
http://breast-cancer-research.com/content/12/2/R21
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(for example, KIT, CYP24A1, ELF5), have the potential to
provide novel prognostic markers or therapeutic targets
in breast cancer.
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